Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance

Journal of Steroid Biochemistry and Molecular Biology

Volumn 95, Issue 1-5, 2005, Pages 173-181

  Johnston, Stephen R D ^a   Martin, Lesley Ann ^b   Head, Julia ^a   Smith, Ian ^a   Dowsett, Mitch ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitors; Endocrine resistance; Fulvestrant; Long term estrogen deprivation; Signal transduction inhibitors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARZOXIFENE; BENZOTHIOPHENE DERIVATIVE; DROLOXIFENE; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; IDOXIFENE; LAPATINIB; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TOREMIFENE; TRASTUZUMAB; UO 126; VOROZOLE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; ENDOCRINE SYSTEM; FATIGUE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; RASH; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 23744473720     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.04.004     Document Type: Conference Paper

References (50)

1. I.E. Smith, and M. Dowsett Aromatase inhibitors in breast cancer N. Engl. J. Med. 348 2003 2431 2442
2. S.R. Johnston, and M. Dowsett Aromatase inhibitors for breast cancer: lessons from the laboratory Nat. Rev. Cancer 3 2003 821 831
3. R.I. Nicholson, R.A. McClelland, J.R.F. Robertson, and J.M.W. Gee Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer Endocr. Relat. Cancer 6 1999 373 387
4. R. Schiff, S.A. Massarweh, J. Shou, L. Bharwani, S.K. Mohsin, and C.K. Osborne Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance Clin. Cancer Res. 10 2004 331S 336S
5. J. Shou, S. Massarweh, C.K. Osborne, A.E. Wakeling, S. Ali, H. Weiss, and R. Schiff Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J. Natl. Cancer Inst. 96 2004 926 935
6. J.M. Knowlden, I.R. Hutcheson, H.E. Jones, T. Madden, J.M. Gee, M.E. Harper, D. Barrow, A.E. Wakeling, and R.I. Nicholson Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 2003 1032 1044
7. J.F. Robertson, R.I. Nicholson, N.J. Bundred, E. Anderson, Z. Rayter, M. Dowsett, J.N. Fox, J.M. Gee, A. Webster, A.E. Wakeling, C. Morris, and M. Dixon Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer Cancer Res. 61 2001 6739 6746
8. A.E. Wakeling, M. Dukes, and J. Bowler A potent specific pure antiestrogen with clinical potential Cancer Res. 51 1991 3867 3873
9. M. Borras, I. Laios, A. el Khissiin, H.S. Seo, F. Lempereur, N. Legros, and G. Leclercq Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells J. Steroid Biochem. Mol. Biol. 57 1996 203 213
10. S. Dauvois, R. White, and M.G. Parker The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling J. Cell. Sci. 106 Pt 4 1993 1377 1388
11. C.K. Osborne, E.B. Coronado-Heinsohn, S.G. Hilsenbeck, B.L. McCue, A.E. Wakeling, R.A. McClelland, D.L. Manning, and R.I. Nicholson Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer J. Natl. Cancer Inst. 87 1995 746 750
12. C.K. Osborne, J. Pippen, S.E. Jones, L.M. Parker, M. Ellis, S. Come, S.Z. Gertler, J.T. May, G. Burton, I. Dimery, A. Webster, C. Morris, R. Elledge, and A. Buzdar Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J. Clin. Oncol. 20 2002 3386 3395
13. A. Howell, J.F. Robertson, J. Quaresma Albano, A. Aschermannova, L. Mauriac, U.R. Kleeberg, I. Vergote, B. Erikstein, A. Webster, and C. Morris Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J. Clin. Oncol. 20 2002 3396 3403
14. S.R. Johnston Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies Clin. Cancer Res. 7 2001 4376 4387 discussion 4411s-4412s
15. ATAC Trialists Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2002 2131 2139
16. H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez-Carrion, C. Boni, A. Monnier, J. Apffelstaedt, R. Smith, H.P. Sleeboom, F. Jaenicke, A. Pluzanska, M. Dank, D. Becquart, P.P. Bapsy, E. Salminen, R. Snyder, H. Chaudri-Ross, R. Lang, P. Wyld, and A. Bhatnagar Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J. Clin. Oncol. 21 2003 2101 2109
17. J.M. Nabholtz, A. Buzdar, M. Pollak, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster, and M. von Euler Anastrozole is superior to tamoxifen as first-line therapy for advanced breast carcinoma in postmenopausal women: results of a North American multicenter randomized trial J. Clin. Oncol. 18 2000 3758 3767
18. C.M. Chan, L.A. Martin, S.R. Johnston, S. Ali, and M. Dowsett Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation J. Steroid Biochem. Mol. Biol. 81 2002 333 341
19. L.A. Martin, I. Farmer, S.R. Johnston, S. Ali, C. Marshall, and M. Dowsett Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation J. Biol. Chem. 278 2003 30458 30468
20. M.-H. Jeng, M.A. Shupnik, T.P. Bender, E.H. Westin, D. Bandyopadhyay, R. Kumar, S. Masamura, and R. Santen Estrogen receptor expression and function in long-term estrogen deprived human breast cancer cells Endocrinology 139 1998 4164 4174
21. W.S. Shim, M. Conaway, S. Masamura, W. Yue, J.P. Wang, R. Kmar, and R.J. Santen Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo Endocrinology 141 2000 396 405
22. M.H. Jeng, W. Yue, A. Eischeid, J.P. Wang, and R.J. Santen Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells Breast Cancer Res. Treat. 62 2000 167 175
23. R.L. Stephen, L.E. Shaw, C. Larsen, D. Corcoran, and P.D. Darbre Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells J. Biol. Chem. 276 2001 40080 40086
24. R.A. Campbell, P. Bhat-Nakshatri, N.M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri Phosphatidylinositol 3-Kinase/AKT-mediated activation of estrogen receptor alpha. A new model for anti-estrogen resistance J. Biol. Chem. 276 2001 9817 9824
25. L. Perey, R. Paridaens, F. Nole, O. Pagani, H. Bonnefoi, S. Aebi, D. Dietrich, A. Goldhirsch, and B. Thurlimann Fulvestrant as hormonal treatment in postmenopausal women with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial Breast Cancer Res. Treat. 18 2004 S236
26. S. Johnston Fulvestrant and the sequential endocrine cascade for advanced breast cancer Br. J. Cancer 90 Suppl. 1 2004 S15 S18
27. C. Osipo, C. Gajdos, H. Liu, B. Chen, and V.C. Jordan Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer J. Natl. Cancer Inst. 95 2003 1597 1608
28. H. Kurokawa, A.E.G. Lenferink, J.F. Simpson, P.I. Pisacane, M.X. Sliwkowski, J.T. Forbes, and C.L. Arteaga Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells Cancer Res. 60 2000 5887 5894
29. L. Witters, L. Engle, and A. Lipton Restoration of estrogen responsiveness by blocking the HER-2/neu pathway Oncol. Rep. 9 2002 1163 1166
30. S. Pancholi, A. Lykkesfeldt, M. Dowsett, S.R.D. Johnston, and L.-A. Martin Elevated levels of Akt and p90rsk provide tamoxifen-resistant MCF-7 cells with a survival advantage involving Bad and Bcl-2 Proc. Am. Assoc. Cancer Res. 45 2004 5168
31. K. Yu, L. Toral-Barza, C. Discafani, W.G. Zhang, J. Skotnicki, P. Frost, and J.J. Gibbons mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr. Relat. Cancer 8 2001 249 258
32. S.L. Moulder, F.M. Yakes, S.K. Muthuswamy, R. Bianco, J.F. Simpson, and C.L. Arteaga Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo Cancer Res. 61 2001 8887 8895
33. I.R. Hutcheson, J.M. Knowlden, T.A. Madden, D. Barrow, J.M. Gee, A.E. Wakeling, and R.I. Nicholson Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells Breast Cancer Res. Treat. 81 2003 81 93
34. K. Albain, R. Elledge, W.J. Gradishar, D.F. Hayes, E.K. Rowinsky, C. Hudis, L. Pusztai, D. Tripathy, S. Modi, and S. Rubi Open-label phase II multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer Breast Cancer Res. Treat. 76 2002 A20
35. J. Baslega, J. Albanelli, A. Ruiz, A. Lluch, P. Gascon, S. Gonzalez, V. Guillan, S. Sauleda, S.D. Averbuch, and F. Rojo Phase II and tumor pharmacodynamic study of gefitinib in patients with advnaced breast cancer Proc. Am. Soc. Clin. Oncol. 22 2003 A24
36. J.F.R. Robertson, E. Gutteridge, K.L. Cheung, R. Owers, M. Koehler, L. Hamilton, J.M.W. Gee, and R.I. Nicholson Gefitinib (ZD1839) is active in acquired tamoxifen-resistant oestrogen receptor positive and ER-negative breast cancer: results from a phase II study Proc. Am. Soc. Clin. Oncol. 22 2003 A23
37. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, and D.A. Haber Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
38. S.R. Johnston, T. Hickish, P. Ellis, S. Houston, L. Kelland, M. Dowsett, J. Salter, B. Michiels, J.J. Perez-Ruixo, P. Palmer, and A. Howes Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer J. Clin. Oncol. 21 2003 2492 2499
39. S. Chan, M.E. Scheulen, S.R.D. Johnston, K. Mross, M. Piccart, D. Hess, N. Bouxin, and N. Azli A phase II study of two dose levels of CCI-779 in locally advanced or metasatic breast cancer failing prior anthracyclines and/or taxanes regimens Proc. Am. Soc. Clin. Oncol. 22 2003 A774
40. J.M. Gee, M.E. Harper, I.R. Hutcheson, T.A. Madden, D. Barrow, J.M. Knowlden, R.A. McClelland, N. Jordan, A.E. Wakeling, and R.I. Nicholson The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro Endocrinology 144 2003 5105 5117
41. D.W. End, G. Smets, A.V. Todd, T.L. Applegate, C.J. Fuery, P. Angibaud, M. Venet, G. Sanz, H. Poignet, S. Skrzat, A. Devine, W. Wouters, and C. Bowden Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro Cancer Res. 61 2001 131 137
42. L.R. Kelland, V. Smith, M. Valenti, L. Patterson, P.A. Clarke, S. Detre, D. End, A.J. Howes, M. Dowsett, P. Workman, and S.R. Johnston Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer Clin. Cancer Res. 7 2001 3544 3550
43. S.R.D. Johnston, J. Head, M. Valenti, S. Detre, and M. Dowsett Endocrine therapy combined with the farnesyltransferase inhibitor R115777 produces enhanced tumour growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in vivo Breast Cancer Res. Treat. 76 2002 A245
44. C.A. Ellis, M.D. Vos, M. Wickline, C. Riley, T. Vallecorsa, W.G. Telford, J. Zujewskil, and G.J. Clark Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines Breast Cancer Res. Treat. 78 2003 59 67
45. B.J. Long, G. Liu, C.H. Marrinan, S. Black, F. Gheyas, A. Nomeir, M. Liu, P. Kirschmeier, and R. Bishop Combining the farnesyl transferase inhibitor (FTI) lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer cells and tumor xenografts Proc. Am. Assoc. Cancer Res. 45 2004 A3868
46. S.F. Doisneau-Sixou, P. Cestac, J.C. Faye, G. Favre, and R.L. Sutherland Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression Int. J. Cancer 106 2003 789 798
47. J. Rudolf, A. Boulay, S. Zumstein-Mecker, D.B. Evans, T. O'Reilly, and H.A. Lane The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative FAD001 with the aromatase inhibitor letrozole in breast carcinomas Proc. Am. Assoc. Cancer Res. 45 2004 5619
48. S. Massarweh, J. Shou, S.K. Mohsin, M. Ge, A.E. Wakeling, C.K. Osborne, and R. Schiff Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 (Iressa) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors Proc. Am. Soc. Clin. Oncol. 21 33a 2002 A130
49. C.L. Harper-Wynne, N.P.M. Sacks, K. Shenton, F.A. MacNeill, P. Sauven, I.J. Laidlaw, Z. Rayter, S. Miall, A. Howes, J. Salter, M.J. Hills, F.M. Lowe, R. A'Hern, N. Nasiri, D. Doody, J. Iqbal, and M. Dowsett Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer J. Clin. Oncol. 20 2002 1026 1035
50. M. Dowsett, and I. Smith Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer Proc. Am. Soc. Clin. Oncol. 23 2004 11 A537